ArticleJournal of cheminformatics2025
Novel molecule design with POWGAN, a policy-optimized Wasserstein generative adversarial network.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence-driven drug discovery: a deep learning paradigm shift in pharmaceutical research and development.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generative artificial intelligence has the potential to open new vast chemical search spaces, yet existing reinforcement-guided generative adversarial networks (GANs) struggle to produce non-fragmented and property-oriented molecules at scale without compromising other properties. To overcome these limitations, we present Policy-Optimised Wasserstein GAN (POWGAN), a graph-based generator that incorporates a dynamically scaled reward into adversarial training. The scaling factor increases when progress stalls, keeping gradients informative while steadily steering the generator towards user-defined objectives. When POWGAN replaces the loss function in a previous MedGAN architecture, using graph connectivity (non-fragmentation) as the target property, attains 1.00 fully connected quinoline-like molecules, compared to previous 0.62, while maintaining novelty (0.93) and uniqueness (0.95). The resulting model R-MedGAN produces > 12,000 novel quinoline-like, a significant increase over its predecessor under identical experimental conditions. Chemical space visualizations demonstrate that these molecules populate regions not present in the training dataset or MedGAN, confirming genuine scaffold innovation. By achieving a new architecture capable of orienting generative process towards a reward, our study also showed this strategy is capable of progressing towards druglikeness properties. Synthetic Accessibility Scores (SAS) measured by Erlth algorithm between 1 and 6, and lipophilicity measured as LogP between 1.35 and 1.80, both increased the proportion from 8 to 65% and 17% to 45%, respectively, compared to baseline. Our study shows R-MedGAN architecture, incorporating POWGAN loss, is also generalizable for models trained with different molecular scaffolds other than quinoline originally tested in MedGAN (R-MedGAN-QNL). For indole (R-MedGAN-IND) and imidazole (R-MedGAN-IMZ) datasets, connectivity increased from 0.38 and 0.50 up to 1.00 during training. This study provides evidence that an adaptive reward-scaling policy in a Wasserstein GAN can simultaneously guide the generative training towards a reward by enhancing molecular connectivity, expand generative throughput, preserve diversity, and improve drug-likeness properties. By eliminating the limitation trade-off between property optimisation and sample diversity, POWGAN and its R-MedGAN implementation advance the state of the art in molecule-generating GANs and deploys a robust, scalable platform for high-throughput, goal-directed chemical exploration in early-stage drug discovery. These findings underscore the effectiveness of adaptive reinforcement-driven strategies in generative adversarial networks oriented by rewards for molecular discovery. SCIENTIFIC CONTRIBUTION: In this work we introduce POWGAN, a policy-optimized Wasserstein GAN that uses adaptive reward scaling to improve goal-directed molecule generation. Integrated into MedGAN (R-MedGAN), it increases the number of valid, connected, and novel molecules under identical settings while maintaining diversity and drug-likeness. This demonstrates that adaptive reward strategies can jointly enhance molecular topology and property optimization at scale.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.